Table 1 Patient Characteristics (n = 15)
From: Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
Characteristics | No. of Patients | % |
|---|---|---|
Sex | ||
 Female | 3 | 20 |
 Male | 12 | 80 |
Age, years | ||
 Median | 50 | |
 Range | 40–61 | |
ECOG PS | ||
 0 | 15 | 100 |
Histologic subtypes | ||
 Adenocarcinoma | 10 | 66.7 |
 Squamous carcinoma | 4 | 26.7 |
 Adenosquamous carcinoma | 1 | 6.7 |
Tumor stage (AJCC) | ||
 IA | 4 | 26.7 |
 IB | 6 | 40 |
 IIA | 2 | 13.3 |
 IIB | 1 | 6.7 |
 IIIA | 2 | 13.3 |
Lymph node metastasis | ||
 Yes | 2 | 13.3 |
 No | 13 | 86.67 |
History of chemotherapy | ||
 Yes | 12 | 80 |
 No | 3 | 20 |
History of radiotherapy | ||
 Yes | 0 | 0 |
 No | 15 | 100 |